findmyKOL

Vivek Subbiah, MD

Enriched profile

Professor of Medicine (Oncology) and Professor of Pediatrics (Hematology/Oncology); Jeffrey and Christina Bird Professor; Associate Director for Drug Development and Precision Oncology, Stanford Cancer Institute · Stanford University School of Medicine

ORCID↗NPI↗
✓ Full profile
RegionStanford, CA · WestSpecialtyMedical OncologyFocusCancer Genomics and Diagnostics+4
Active KOLfindmyKOL type: NationalLatest publication2026Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Vivek Subbiah is Professor of Medicine (Oncology) and Professor of Pediatrics (Hematology/Oncology); Jeffrey and Christina Bird Professor; Associate Director for Drug Development and Precision Oncology, Stanford Cancer Institute at Stanford University School of Medicine. OpenAlex indexes 1,434 publications with 32,217 citations (h-index 79); ClinicalTrials.gov lists 16 registered studies with this person as an investigator.

Data verified 25 Aug 2026

Overview

Updated 14 Oct 2026

Vivek Subbiah is Professor of Medicine (Oncology) and Professor of Pediatrics (Hematology/Oncology) at Stanford University School of Medicine / Stanford Cancer Institute (Division of Oncology, Department of Medicine). The public record shows 1,434 publications with 32,217 citations (h-index 79), centered on Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, Sarcoma Diagnosis and Treatment. It also documents an investigator role on 12 registered clinical trials.

  • Most recent indexed publication: 2026 · Cancer biotherapy & radiopharmaceuticals
  • Top research focus: Cancer Genomics and Diagnostics
  • 12 registered trials on ClinicalTrials.gov

Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Lymphoma3 trialsSarcoma2 trialsMultiple Myeloma2 trialsPancreatic Cancer2 trialsComa2 trialsHepatobiliary Cancer2 trialsHead & Neck Cancer2 trialsCholangiocarcinoma2 trialsLung Cancer (NSCLC/SCLC)1 trialColorectal Cancer1 trialBreast Cancer1 trialProstate Cancer1 trialBladder / Urothelial Cancer1 trialKidney Cancer / RCC1 trialGastroesophageal Cancer1 trialOvarian / Gynecologic Cancer1 trialMelanoma1 trialLeukemia (AML/ALL/CML/CLL)1 trialNeuro-Oncology / Glioma1 trialLeukemia, Myeloid, Acute1 trialStomach Neoplasms1 trialPrecursor Cell Lymphoblastic Leukemia-Lymphoma1 trialColonic Neoplasms1 trialUterine Cervical Neoplasms1 trialRectal Neoplasms1 trialEsophageal Neoplasms1 trialHodgkin Disease1 trialLiver Neoplasms1 trialKidney Neoplasms1 trialFallopian Tube Neoplasms1 trialAstrocytoma1 trialNasopharyngeal Carcinoma1 trialSkin Neoplasms1 trialNeuroendocrine Tumors1 trialWaldenstrom Macroglobulinemia1 trialSexually Transmitted Diseases1 trialMesothelioma1 trialTesticular Neoplasms1 trialAnus Neoplasms1 trialLaryngeal Neoplasms1 trialBone Neoplasms1 trialBile Duct Neoplasms1 trialUterine Neoplasms1 trialSalivary Gland Neoplasms1 trialVulvar Neoplasms1 trialLiposarcoma1 trialPheochromocytoma1 trialSarcoma, Kaposi1 trialVaginal Neoplasms1 trialSarcoma, Synovial1 trialTongue Neoplasms1 trialCarcinoid Tumor1 trialNeoplasms, Unknown Primary1 trialPenile Neoplasms1 trialChondrosarcoma1 trialAppendiceal Neoplasms1 trialUreteral Neoplasms1 trialCarcinoma, Adenoid Cystic1 trialParathyroid Neoplasms1 trialAdrenal Gland Neoplasms1 trialCarcinoma, Small Cell1 trialThymus Neoplasms1 trialCysts1 trialMultiple Endocrine Neoplasia1 trialBrain Stem Neoplasms1 trialTrophoblastic Neoplasms1 trial

Research focus

OpenAlex concept fingerprint
Cancer Genomics and DiagnosticsLung Cancer Treatments and MutationsSarcoma Diagnosis and TreatmentCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Drugs & molecules

across trials, industry payments and publications
Keytrudageneric · PembrolizumabClinical trials1Industry payments3Publications3Retevmogeneric · SelpercatinibClinical trials—Industry payments2Publications11Gavretogeneric · PralsetinibClinical trials—Industry payments3Publications8Mekinistgeneric · TrametinibClinical trials—Industry payments2Publications7Enhertugeneric · TrastuzumabClinical trials—Industry payments7Publications1Tafinlargeneric · DabrafenibClinical trials—Industry payments1Publications7SapanisertibClinical trials2Industry payments—Publications3VemurafenibClinical trials1Industry payments—Publications4Zepzelcageneric · LurbinectedinClinical trials—Industry payments3Publications2EverolimusClinical trials1Industry payments—Publications3PaclitaxelClinical trials1Industry payments—Publications3CarboplatinClinical trials1Industry payments—Publications2

Works with

trial sponsors and companies reporting payments
E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments22Pfizer Inc.Clinical trials—Industry payments16Novartis Pharmaceuticals CorporationClinical trials—Industry payments14AstraZeneca Pharmaceuticals LPClinical trials—Industry payments9Eli Lilly and CompanyClinical trials—Industry payments8Daiichi Sankyo Inc.Clinical trials—Industry payments7F. Hoffmann-La Roche AGClinical trials—Industry payments7M.D. Anderson Cancer CenterClinical trials6Industry payments—Abbvie Inc.Clinical trials—Industry payments5Celgene CorporationClinical trials—Industry payments5Array Biopharma IncClinical trials—Industry payments4Jazz Pharmaceuticals Inc.Clinical trials—Industry payments4SpringWorks Therapeutics, Inc.Clinical trials—Industry payments4Bayer Healthcare Pharmaceuticals Inc.Clinical trials—Industry payments3Eisai Inc.Clinical trials—Industry payments3Incyte CorporationClinical trials—Industry payments3Merck Sharp & Dohme LLCClinical trials—Industry payments3Regeneron Healthcare Solutions, Inc.Clinical trials—Industry payments3Rigel Pharmaceuticals, Inc.Clinical trials—Industry payments3AstraZeneca UK LimitedClinical trials—Industry payments2Blueprint Medicines CorporationClinical trials—Industry payments2Gilead Sciences, Inc.Clinical trials—Industry payments2Lilly USA, LLCClinical trials—Industry payments2Otsuka Pharmaceutical Co., Ltd.Clinical trials—Industry payments2Alfasigma S.p.A.Clinical trials1Industry payments—BeOne Medicines USA, Inc.Clinical trials—Industry payments1Boehringer Ingelheim Pharmaceuticals, Inc.Clinical trials—Industry payments1BPGbioClinical trials1Industry payments—Deciphera Pharmaceuticals Inc.Clinical trials—Industry payments1EMD Serono, Inc.Clinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,434publications

Distinct works indexed by OpenAlex, matched via ORCID; 142 in PubMed.

32,217citations

Total citations across indexed works.

79h-index

Hirsch index (OpenAlex). i10-index 405.

Clinical & industry

trials, payments and federal funding
16clinical trials

Investigator role on registered studies.

View trials ↓
43companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 14 Oct 2026

Listed as an investigator on 16 registered studies on ClinicalTrials.gov. The most recent:

All 16 trial records: search, sort and filter.Explore →

Industry payments

43 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 65 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Sensory organs

    100%
    Corticosteroid100%
    Dexamethasone sodium phosphate100%
    Part B, office-administered≥13 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 14 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 142 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
    1,735 citations2015
    doi.org ↗
  2. 02
    Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic <i>BRAF</i> V600–Mutant Anaplastic Thyroid Cancer
    886 citations2017
    doi.org ↗
  3. 03
    Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
    837 citations2020
    doi.org ↗
  4. 04
    Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
    776 citations2020
    doi.org ↗
  5. 05
    The next generation of evidence-based medicine
    530 citations2023
    doi.org ↗
All 1,434 cited works: search, sort and filter.Explore →

Network

Updated 14 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

David S. Hong477Funda Meric‐Bernstam385Sarina A. Piha‐Paul353Aung Naing336Filip Jankú323Siqing Fu316Apostolia M. Tsimberidou290Daniel D. Karp263Razelle Kurzrock185Gerald S. Falchook147Ralph Zinner138Jennifer J. Wheler128Shubham Pant128Kenneth R. Hess126Alison M. Schram118Jason Roszik117Beni B. Wolf112Kai Yu Jen111Lipika Goyal110Vaibhav Sahai110Oleg Schmidt‐Kittler109Fabien Ricard109Cori Ann Sherwin108Debjani Pal105James Watters105Alexander M. Taylor105Suneel Kamath105Lindsey Foster105Roberto Valverde105Dejan Maglic105Songping Zhao105Dina A. Sharon105Donald A. Bergstrom105Damian J. Houde105Nastaran Gerami-Moayed105Hakan Günaydin105Pelin Ayaz105Jessica B. Casaletto105Demetri T. Moustakas105Patrick J. O’Hearn105

Online presence

Updated 14 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/vivek-subbiah-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • Instagram

    instagram.com/viveksubbiahmd

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗
  • LinkedIn

    linkedin.com/in/vivek-subbiah-md-bb968633

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
  • LinkedIn

    linkedin.com/in/viveksubbiah

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
  • Bluesky

    bsky.app/profile/viveksubbiah.bsky.social

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bsky.app ↗
  • ResearchGate

    researchgate.net/profile/Vivek-Subbiah

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
  • X / Twitter

    x.com/VivekSubbiah

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com ↗

Mentions by others

where others cite or feature them
  • Other

    esmo.org/about-esmo/biographies/vivek-subbiah

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →esmo.org ↗
  • Other

    onclive.com/authors/vivek-subbiah-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
  • X / Twitter

    X/Twitter: @VivekSubbiah - bio: 'Drug Development| Precision Oncology| Tissue-Agnostic Precision Medicine #Oncologist, #Phase1trials, #PrecisionMedicine'

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com ↗
  • LinkedIn

    LinkedIn: Vivek Subbiah, MD - listed as Professor at Stanford University

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 14 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Co-Chair

    'Advances in Precision Oncology' Clinical Trials Mini Symposium, AACR Annual Meeting 2026

    2026
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗
  • Member

    ESMO Precision Oncology Working Group

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗
  • Leadership/committee involvement in ASCO

    AACR, and ESMO (tumor-agnostic precision oncology programming)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ascopost.com ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • Former: Chief

    Early-Phase Drug Development, Sarah Cannon Research Institute

    2026
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scri.com ↗
  • Former: Associate Professor

    Department of Investigational Cancer Therapeutics, and Medical Director, Clinical Center for Targeted Therapy, UT MD Anderson Cancer Center

    2023
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
  • Executive Medical Director for Cancer Novel Therapies and Clinical Trial Network Development

    Stanford Health Care

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.stanford.edu ↗
  • Member

    Stanford Cancer Institute

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗

Media & interviews

press, podcasts and appearances
  • Host

    JAMA Oncology podcast episode with Dr. Michael Postow (Memorial Sloan Kettering) on immunotherapy for melanoma brain metastases (AMA Ed Hub platform)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗
  • Featured video/commentary contributor

    OncLive (tissue-agnostic therapies, precision oncology)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
  • Featured interview

    AJMC - "AI Should Support Clinicians, Not Replace Them" (Patient-Centered Oncology Care conference)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ajmc.com ↗
  • Featured interview

    AJMC - ESMO Congress coverage on tumor-agnostic cancer therapies

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ajmc.com ↗
  • Active public X/Twitter account (@VivekSubbiah)

    ~40.5K followers, oncology/precision medicine commentary; explicitly tagged by The ASCO Post's official account announcing his Stanford appointment

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com ↗

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.